DNA Script, a pioneer in DNA synthesis that provides scientists with rapid, on-demand access to high-quality DNA, today announced distribution agreements with Gencell, Bio-Medical Science Co. (BMS), and BioStream Co. to expand global access to the company’s SYNTAX® platform for decentralized in-house and on-demand oligonucleotide production. Under the agreement, Gencell will distribute SYNTAX throughout Latin America, Bio-Medical Science will cover South Korea, and BioStream will support customers in Japan.
This expansion supports DNA Script’s strategy to expand the global adoption of SYNTAX and make DNA more quickly and reliably accessible to researchers far from major oligonucleotide production centers in Europe and the United States. Each distributor is an established life and health sciences company with a strong regional network, providing local access to DNA synthesis capabilities without relying on overseas manufacturing.
Oligonucleotides are critical inputs for a wide range of applications, but researchers far from large synthesis centers face project delays due to long turnaround times and logistical constraints. DNA Script’s automated benchtop SYNTAX platform addresses these challenges by enabling researchers to synthesize ssDNA oligonucleotides directly in the lab in just a few hours, moving models from centralized supply chains to local DNA production and ensuring that geography does not determine the speed of science.
We are pleased to enter into these new partnerships as part of our strategy to expand global access and availability of ssDNA oligos and make them available to researchers around the world. These distributor agreements expand global access to our platform, supporting our continued growth and enabling researchers to access oligonucleotides faster and more reliably, regardless of location. ”
Mark Montserrat, CEO, DNA Script
Fabio Andres Zapata, CEO of Gencell, said: “This partnership represents a fundamental step towards accelerating innovation in Latin America. By bringing technologies like SYNTAX closer to researchers in the region, we will shorten development times and help advance local biomanufacturing. We are proud to strengthen the region’s scientific and technological capabilities and position Latin America as an increasingly competitive player in global science and biotechnology.”
Dukhyun Lim, Vice President of BMS Biomedical Sciences, commented: “SYNTAX provides researchers with greater control and speed of oligonucleotide production, allowing greater independence and control over project workflows. We are pleased to support its availability in Korea.”
Tsuyoshi Iwabuchi, President of BioStream, added: “This partnership strengthens our ability to provide advanced life science technologies across Japan, allowing our customers to reduce their dependence on overseas synthesis and longer delivery times.”
